Shustik, J. 2025. Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor. Canadian Hematology Today. 4, 3 (Dec. 2025), 24–35. DOI:https://doi.org/10.58931/cht.2025.4379.